Clinical Profile and Treatment of Multiple Myeloma at a Tertiary Hospital in Kenya: A Five‐Year Retrospective Review

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Wanjiku Gichuru, Nicholas A. O. Abinya, Andrew Odhiambo, Fredrick C. F. Otieno, Simon Harrison, Matilda Ong’ondi
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Advances in Hematology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns
by: Csaba Siffel, et al.
Published: (2025)

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study
by: Iuliana Vaxman, et al.
Published: (2026)

Multiple Myeloma Unpacked
by: Francesca Gay, et al.
Published: (2025)

Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma
by: Tom Schlusemann, et al.
Published: (2026)

Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined
by: Ruben Van Dijck, et al.
Published: (2025)

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study
by: Dong Liang, et al.
Published: (2025)

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia
by: Jana Gregorova, et al.
Published: (2025)

Optical Genome Mapping ( OGM ): Validation and Clinical Utility in the Cytogenetic Diagnosis of Multiple Myeloma
by: Adela Cisneros, et al.
Published: (2025)

Treatment of Relapsed/Refractory t(11;14) Multiple Myeloma and High‐Risk Myelodysplastic Syndrome With Venetoclax
by: Allison O. Taylor, et al.
Published: (2025)

Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow‐Up of a Multicenter, Retrospective Real‐World Experience With 321 Cases Outside of Controlled Clinical Trials
Published: (2025)

Cutting‐Edge Technologies to Decode Tumor Microenvironment in Multiple Myeloma
by: Doriana Gramegna, et al.
Published: (2026)

Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution
by: Meletios A. Dimopoulos, et al.
Published: (2025)

Real‐World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15‐Year Period
by: Xue Yang, et al.
Published: (2025)

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
by: Michèle Hoffmann, et al.
Published: (2025)

Soluble B‐cell Maturation Antigen in Multiple Myeloma and Correlation With Response to Therapy
by: Souvik Saha, et al.
Published: (2025)

Genomic Proximity Mapping for Identification of Chromosomal Aberrations in Multiple Myeloma
by: Richard K. Kandasamy, et al.
Published: (2026)

Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma
by: Mickael Tordjman, et al.
Published: (2026)

Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma
by: Zhiqiang Song, et al.
Published: (2026)

A Case Report Supporting the Use of Teclistamab in Multiple Myeloma With CNS Involvement
by: Jessica Blackman, et al.
Published: (2025)

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights
by: Benjamin Podvin, et al.
Published: (2026)

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non‐Response
by: Rahul Banerjee, et al.
Published: (2025)

Maintenance Therapy in the Era of Quadruplets for Multiple Myeloma: When, What, and for How Long?
by: Hira Mian, et al.
Published: (2025)

Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials
by: Ioannis Ntanasis‐Stathopoulos, et al.
Published: (2025)

A Rare Case Report of Immunoglobulin D Subtype Multiple Myeloma Complicated With Hyperlipidemia
by: Liping Yang, et al.
Published: (2026)

Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event Management
by: Eirini Katodritou, et al.
Published: (2025)

Evaluation of Delayed Initiation of Lenalidomide Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
by: Koji Kawamura, et al.
Published: (2025)

Why We Do Not Recommend That People With High‐Risk Smoldering Myeloma Receive Treatment
by: Ghulam Rehman Mohyuddin, et al.
Published: (2025)

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review
by: Ioannis Ntanasis‐Stathopoulos, et al.
Published: (2026)

Transcriptome Analysis Identifies Functional and Prognostic Hypoxia‐Associated Genes in Multiple Myeloma
by: Lijia Hou, et al.
Published: (2025)

Lymphocyte Kinetics and Outcomes of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma With Out of Specification Products
by: Sarah Dingli, et al.
Published: (2025)

Circadian Deregulation in Multiple Myeloma: BMAL1 / CLOCK Expression Patterns and Diagnostic Performance
by: Hamide Albayrak, et al.
Published: (2026)

Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front‐Line Daratumumab Lenalidomide and Dexamethasone
by: Ricardo D. Parrondo, et al.
Published: (2026)

Targeting GPRC5D With CAR‐T Cells in Relapse/Refractory Multiple Myeloma: Case Report and Literature Review
by: Sijia Yan, et al.
Published: (2025)

Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30‐Year Experience of the Greek Myeloma Study Group on 175 Patients
by: Eirini Katodritou, et al.
Published: (2025)

Cardiac Amyloidosis AI‐ECG Model is Useful in Predicting Outcomes in Multiple Myeloma Patients Without Amyloidosis Undergoing Autologous Stem Cell Transplant
by: Melinda S. Y. Tan, et al.
Published: (2026)

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
by: Enrica Antonia Martino, et al.
Published: (2025)

Extramedullary Disease—Achilles Heel in Myeloma?
by: Shaji Kumar, et al.
Published: (2025)

Accurate Predictor for Successful Collection of Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Lymphoma
by: Hongyan Li, et al.
Published: (2025)

Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis
by: Lucio N. Gordan, et al.
Published: (2025)

Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma
by: Suwen Yang, et al.
Published: (2024)